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INTRODUCTION 
 
Dengue fever is caused by flavi virus and is spread by 
aedes mosquito mostly aedes aegypti. It has a mean incubation 
period of 2-5 days and has been seen to occur as seasonal 
outbreaks. 
Dengue fever can occur with varied spectrum of 
presentations. From the inconspicuous viral fever syndrome to 
the fatal dengue shock syndrome/dengue haemorrhagic fever. 
There is a need for a simple predictive marker for patients at risk 
of progressing. 
Various metabolic abnormalities have been found in 
dengue patients, namely, elevated liver enzymes, low sodium 
and ionised calcium levels, hyponatremia, increased urinary 
protein levels. 
Proteinuria has been used as a method for assessing 
severity of dengue .proteinuria is best measured by 24 hrs 
urinary protein but it is a cumbersome procedure. Various texts 
show that urine spot PCR as an acceptable alternative. Normal 
urine spot PCR is less than 30mg/mmol. 
WHO 2009 guidelines classify dengue fever into dengue 
fever, dengue fever with warning signs and severe dengue fever. 
Dengue fever is patients with fever, rash, vomiting, aches and 
leucopoenia. 
The warning signs in dengue are  
• Abdominal pain or tenderness 
• Persistent vomiting 
• Clinical fluid accumulation 
• Mucosal bleed 
• Lethargy, restlessness 
• Liver enlargement >2 cm 
• Laboratory: increase in HCT concurrent with rapid decrease in 
platelet count 
Severe dengue is defined as those with 
Severe plasma leakage leading to: 
• Shock (DSS) 
• Fluid accumulation with respiratory distress 
Severe bleeding as evaluated by clinician 
Severe organ involvement 
• Liver: AST or ALT >=1000 
• CNS: Impaired consciousness 
• Heart and other organs. 
WHO guidelines 1997 defines dengue hemorrhagic fever as 
those with  
 positive tourniquet test, petechiae, ecchymoses or purpura, 
bleeding from injection sites or other locations, malena or 
hematemesis, 
 thrombocytopenia <1,00,000/mm3 
 Plasma leakage as evidenced by increase in hematocrit 
20% from baseline, decrease in hematocrit >20% after 
volume replacement, pleural effusion, ascites and 
hypoproteinemia. 
Dengue shock syndrome is defined by Patients with dengue 
hemorrhagic fever with tachycardia. Pulse pressure <20mmhg, 
hypotension for age, cold skin, restlessness. 
A laboratory criterion for confirmation is usually done by 
detection of IgM antibody. 
Vasanwala et al showed a positive correlation with dengue 
hemorrhagic fever and dengue shock syndrome. 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVE OF THE STUDY: 
• To study daily urine spot protein creatinine Ratio in 
dengue fever patients 
• To use it to predict patients at risk for developing 
complications  
• To calculate its sensitivity and specificity as a prognostic 
tool 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
Dengue infections are caused by the four distinct dengue 
virus serotypes (DENV1, DENV2, DENV3, DENV4) of the 
Flaviviridae family of arboviruses are the most important vector 
borne diseases in humans, in geographical distribution, 
morbidity and mortality. The global burden of dengue has 
increased at least thirty times over the last 3 decades and there 
are now 2.5 billion people at risk of the disease. Annual dengue 
infections estimate stands at 50 million for symptomatic 
infections and about four hundred million for asymptomatic 
infection. Among these about 500000 severe cases of dengue 
hemorrhagic fever/dengue shock syndrome and 20,000 deaths 
occur with most of them being children and adolescents. The 
most commom vector is Aedes.aegypti. Clinical spectrum of 
dengue can range from, from a mild febrile illness known as 
‘dengue fever’ through to ‘severe dengue’, previously known as 
dengue haemorrhagic fever (DHF), which is characterized by 
capillary leakage leading to hypovolaemic shock, organ 
impairment and bleeding complications. There are currently no 
antiviral drugs and and the management relies on judicious fluid 
replacement of the severe cases. A vaccine dengue vaccia is 
under trial. The efficacy of which would be established in the 
near future. 
 
Epidemiology  
 
Dengue is occurs between 30°N and 40°S, where 
environment is optimal for  Aedes mosquitoes to transmit the 
dengue virus. 
Like its sibling the yellow fever it is likely that dengue virus was 
also transmitted by the slave trade and world wars across 
various countries. The first recorded outbreak of dengue 
occurred in Pennsylvania in USA.A similar outbreak was alaso 
reported in spain during the same time. The victims suffered 
severe pain which led to the term Break bone fever. Next 
occurred in the Australian mining towns. 
After the world wars trade flourished between nations and 
travel became rampant leading to spread to new frontiers for the 
dengue virus. During the 1950s newer forms of the disease 
began to appear. The Thai hemorrhagic fever (Dengue 
hemorrhagic fever) which also occurred in surrounding nations. 
The trend continues and now over 70% of the global dengue 
cases occurs in Asia. 
 
 Dengue transmission occurs throughout the year in 
endemic tropical areas; however, in most countries there is a 
distinct seasonal pattern, with increased transmission usually 
associated with the rainy season. Outbreaks occur most 
frequently in areas where multiple serotypes of dengue virus are 
simultaneously endemic or sequentially epidemic and infections 
with heterologous types are frequent. In endemic areas dengue 
occurs most frequently in children aged between 2 and 15 years. 
Severe dengue is usually associated with secondary dengue 
infection and during primary infection in infants less than 1 
year, born to dengue-immune mothers. It is clear that dengue 
and other arboviruses with similar ecology had a widespread 
distribution in the tropics as long as 200 years ago. 
 DENGUE VIRUS: 
The dengue virus is a member of Flavivirus genus in the 
family Flaviviridae. It is a single-stranded enveloped RNA 
virus, 30 nm in diameter. There are 4 closely related but distinct 
serotypes (DENV1–4). They have antigens that cross-react with 
other members of the same genus namely, yellow fever, 
Japanese encephalitis and West Nile viruses.  
  All 4 serotypes of DENV evolved independently from 
ancestral sylvatic viruses and have become both ecologically 
and evolutionarily distinct. The evolution of dengue virus is 
differerent in many important aspects from other flaviviruses, 
though they share many of the clinical features such as 
production of severe fever, headache, myalgia, hepatitis, 
encephalitis and haemorrhage. according to Vasilakis (Vasilakis 
et al., 2010) more detailed phylogenetic studies suggest an 
Asian origin for the dengue virus, where sylvatic cycles between 
non-human primates and Aedesmosquitoes arose. Subsequent 
evolutions resulted in four antigenically and phylogenetically 
distinct serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. 
Each of these four serotypes developed independently into an 
endemic cycle of transmission between humans and Aedes 
albopictus . This endemic cycle is separate from the sylvatic 
cycle. So, urban cycles of DENV can no longer be considered 
zoonotic. 
The dengue evolves at a constant rate and the past strains 
have been in circulation with humanity for the past century. 
Genetic variations are also observed in between dengue viruses 
even from same countries, a proof of their diversity. The past 
three decades have seen a spurt in infections with DENV-2 and 
DENV-3. There are five genotypes identified in DENV-1; five 
in DENV-2; four in DENV-3; and four in DENV-4. Some of 
these subtypes differ in virulence and ability to cause disease. 
 
 
Transmission 
Dengue virus is transmitted from human to human by 
different species of Aedes mosquitoes. DENV circulation occurs 
in two cycles:  
1) endemic/epidemic cycle between humans and peridomestic 
mosquitoes, Aedes aegypti and Ae. albopictus  
2) a sylvatic enzootic cycle between non-human primates and 
several arboreal Aedes species. 
  Aedes aegypti is the most efficient of the mosquito vectors 
because of its domestic habits. The female mosquito feeds on 
humans during the day. After feeding on an infected person 
whose blood contains the virus, the female Ae. aegypti can 
transmit dengue, either immediately by a change of host when 
its feeding is interrupted or after an incubation period of 8–10 
days, during which time, the virus multiplies in the salivary 
glands. Once infected, the mosquito host remains infective for 
life (30–45 days). Ae. albopictus, Ae. polynesiensis and several 
species of the Ae. Scutellaris complex are other aedes species 
capable of transmission. Each of the species have their own 
particular geographical distribution and they are in general less 
efficient vectors than Ae. aegypti. Transovarian transmission of 
dengue viruses has been documented. Their epidemiological 
importance has not yet been established. 
 
 
 
 
Pathogenesis 
The strong association between the development of severe 
disease in secondary dengue and the observation that 
complications occur when the viraemia is in steep decline, has 
led to the suggestion that the pathogenesis of severe dengue is 
immune mediated. Halstead in the 1970s proposed the ‘antibody 
dependent immune enhancement theory’ (ADE) based on in 
vitro and primate studies. This association of sequential dengue 
infections being a risk factor for severity has been confirmed 
repeatedly in epidemiological studies, from different parts of the 
world. In addition, a particular sequence of infecting serotypes 
have been linked to severe disease, with several studies 
suggesting severe dengue is more common in a secondary 
infection with DENV2. During the second infection with a 
different dengue serotype, pre-existing antibody from the first 
infection fails to neutralize and may instead enhance viral 
uptake and replication in mononuclear cells. The resulting 
higher viral load has been linked to disease severity. Other 
factors that may contribute to the pathogenesis of severe dengue 
include more virulent strains of the virus, host genetic factors, 
age and comorbidities.  
HUMORAL IMMUNE RESPONSE  
After an acute phase of infection by a particular dengue 
serotype, there is an antibody response to all four dengue 
serotypes. There is a long-lasting immunity to the homologous 
serotype of the infecting strain. A cross-reactive heterotypic 
immunity to all serotypes has been reported for period of 2–12 
months following primary infection. The waning cross-reactive 
heterotypic antibody causes the occurrence of severe dengue 
through ‘antibody dependent enhancement’. The heterologous 
antibody acquired from a previous infection fails to neutralize 
the current infecting serotype, on the contrary it enhances the 
viral uptake into Fcy receptor-bearing cells, particularly 
monocytes and macrophages. ADE, in addition to facilitating 
viral entry into cells, also increases viral replication within the 
cells, through alterations of innate and adaptive intracellular 
antiviral mechanisms. Further research has proven that the 
antibodies in high titres fails to neutralize the virus. A different 
example of ADE is in the setting of severe primary dengue in 
infants born to dengue-immune mothers. Maternally derived 
IgG antibody takes 4-12 months to disappear from the childs 
circulation. An infection by dengue virus may result in the 
catastrophic dengue hemorrhagic fever through the antibody 
mediated enhancement. 
CELL-MEDIATED IMMUNITY 
The cellular immune response is vital in controlling 
dengue infections, but newer studies have concluded that cell 
mediated immunity has a major role to play in the severity of 
dengue. The severity has been attributed to the increased T cell 
activity which provides no use in controlling the virus. 
Activated and infected monocytes and endothelia release with 
their lysis .TNF-α, IL-1, platelet-activating factor (PAF), IL-8, 
and RANTES, act in synergy with lymphokines, histamine, and 
virus and immune complex–induced C3a and C5a cause the 
temporary vascular endothelial dysfunction that leads to plasma 
leakage. While activated cells responding to cross-reactive 
antigens predominate over primary responses to the infecting 
virus, following the paradigm of original antigenic sin, they are 
marked for apoptosis and are ineffective in viral clearance, and 
they may be a source of cytokines with a negative clinical effect. 
A study investigating T-cell responses to the entire dengue 
proteome, showed that the response was most marked to the 
non-structural protein 3 (NS3), with high cytokine and low 
CD107a (a marker of cell degranulation) predominating. This 
suggests that in severe dengue the low cytotoxic potential of the 
T cells fails to obtain early viral control, instead high cytokine-
producing cells dominate the response with the excessive pro-
inflammatory cytokines causing the tissue damage and plasma 
leakage. Other studies have linked disease severity to cellular 
markers of activation in plasma including interleukin-6 and 
soluble IL-2 receptor. 
 
 
 
 
COMPLEMENT 
Complement activation has been suggested to play a role 
in the pathogenesis of dengue. Studies have shown cross-
reactive antibodies to the dengue virus can activate complement 
at the surface of endothelial cells. The release of C3a and C5a 
anaphylatoxins has been associated temporally with the onset of 
plasma leakage and shock. High levels of the major non-
structural protein NS1 has been linked to disease severity. A 
study in Thailand demonstrated that NS1 was able to activate 
complements, directly on the endothelial cells infected by 
dengue virus, leading to local and systemic generation of 
anaphylatoxin C5a and the terminal SC5b-9 complexes. The 
plasma levels of NS1 and SC5b-9 complexes correlated 
positively with disease severity and these complexes were 
detected in pleural fluid from the patients with severe dengue. In 
addition, NS1 may evade immune system by modulating the 
classical and lectin complement pathways through reduced 
functional capacity of C4. These studies suggest a possible role 
for complement in the pathogenesis of severe dengue, both 
through excessive local activation at endothelial surfaces 
contributing to vascular leakage as well as immune modulation 
leading to a higher viraemia. Recent animal studies tend to 
suggest that complements may also have a protective role. The 
C1q and Mannose binding lectin may play a crucial role 
inactivating DENV2. And patients with reduced MBL were 
shown to have greater severity. 
HISTOPATHOLOGY: 
From animal studies, after inoculation the dengue virus 
reaches the regional lymph nodes through the dendritic cells and 
disseminates to the reticuloendothelial system like spleen and 
also other organs in which it multiplies and from which it enters 
the blood causing the secondary viremia. Skin lesions in 
uncomplicated dengue fever seen in human were studied by 
biopsy. The chief pathology occurred around the small  blood 
vessels and consisted of endothelial swelling, perivascular 
oedema and mononuclear cell infiltration. Extensive 
extravasation of blood without inflammatory changes were 
observed in the petechial lesions. Significant changes found in 
major organ systems are  
• vasodilatation, congestion, perivascular haemorrhage and 
edema of arterial walls 
• Proliferation of RE cells with increased phagocytic activity 
were observed 
• The lymphoid tissues showed increased activity of the B 
lymphocytes with proliferation of plasma cells and 
lymphoblastoid cells 
• In the liver shows focal necrosis of the hepatocytes and 
Kupffer cells, with formation of Councilman-like bodies 
• Dengue virus antigen is found predominantly in cells of the 
spleen, thymus and lymph nodes, in Kupffer cells and in the 
sinusoidal lining cells of liver and alveolar lining cells of the 
lung. 
 
 
PATHOPHYSIOLOGY: 
The hallmarks of severe dengue are plasma leakage and 
abnormal haemostasis. Clinical evidence supporting plasma 
leakage includes a rapid rise in haematocrit, hypoproteinaemia, 
pleural effusions and ascites and reduced plasma volume, 
leading to haemodynamic compromise and hypovolaemic shock. 
Microvascular leakage has been demonstrated using the non-
invasive technique of strain gauge plethysmography. A study 
showed that the filtration capacity was higher in DHF patients 
than controls, but did not show a difference between the severity 
grades of DHF. They also showed that age-related changes 
occur in microvascular permeability, with children having 
higher filtration capacity than adults, which would explain why 
dengue shock syndrome is more common in childhood. The 
transient nature of the leakage implies a functional increase in 
vascular permeability. The microvascular leak occurs when the 
viral load is reducing and indicating that immune response is 
responsible for the detrimental effects. Disruption in the 
endothelial glycocalyx layer has been implicated, through 
immune-mediated mechanisms by the virus or the NS1 antigen 
adhering to the endothelial layer. The NS1 antigen is a 
glycoprotein secreted from dengue-infected cells and is required 
for viral replication. Studies have shown that NS1 can 
selectively bind to heparan sulphate in the glycocalyx layer of 
microvascular endothelial cells. Thus facilitating immune 
complex formation and antibody-dependent complement 
activation causing the endothelial damage and microvascular 
leakage. The vascular leakage and hypoproteinaemia seen in the 
blood at defervescence is also associated with proteinuria. The 
proteinuria tends to occur more frequently in severe dengue and 
urinary protein/creatinine ratio has been suggested as a predictor 
of progression to severe disease. A study in Vietnamese children 
demonstrated a reduction in different size proteins in plasma 
was associated with increased fractional urinary clearance of the 
same proteins. The proteinuria resolves in the convalescent 
period and there is generally no associated renal damage with no 
increase in creatinine noted. A transient glomerulonephritis has 
been suggested from renal biopsies, with deposition of dengue 
immune complexes in the glomerular basement membrane. 
The abnormalities in haemostasis and hemotology seen in 
dengue infections include the following: 
 (1) vasculopathy;  
(2) thrombopathy, due impaired platelet functioning and 
production leading to moderate to severe thrombocytopenia 
 (3) coagulopathy, due to activation of the coagulation system 
and fibrinolysis, later stages of severe disease causing 
disseminated intravascular coagulation (DIC) 
 (4) bone marrow changes, include depression of all elements of 
marrow , with maturation arrest of megakaryocytes even during 
the early phase of the illness, which is reversed after 
defervescence period. 
The most consistent finding in dengue infections is a 
transient thrombocytopenia. The exact underlying mechanism 
still remains unclear. Studies suggest that it may be 
multifactorial, including: 
 suppression of megakaryocytopoiesis 
  increased  platelet clearance by DENV-induced apoptosis 
 antiplatelet antibodies. 
 Activation of the coagulation system and fibrinolysis has 
been demonstrated in various studies and is more pronounced in 
severe cases. One study showed that persistently elevated levels 
of tissue activator inhibitor levels and an increased thrombin-
antithrombin to plasmin-antiplasmin ratio was associated with 
poorer outcomes in dengue patients. Other studies have shown 
that mild prolongation of prothrombin time and partial 
thromboplastin time and reduced fibrinogen are also associated 
with poorer outcomes. Fibrinogen degradation products are 
rarely raised, however not to levels consistent with a classical 
DIC picture. Theories to explain these coagulation 
abnormalities’ include; through capillary leakage various 
coagulation factors are lost and leading to the coagulation 
abnormalities. The prolongation of the PT and APTT also 
coincides with maximal vascular leakage and is more 
pronounced in these severe patients. In vitro studies have shown 
that the virus can bind and activate plasminogen and moreover 
cross-reactive antibodies to plasminogen have been 
demonstrated in acute and convalescent serum of dengue 
patients. 
CLINICAL FEATURES: 
Dengue fever presents with a wide spectrum of clinical 
features, from a simple febrile illness to severe features of 
plasma leakage like dengue hemorrhagic fever or Dengue shock 
syndrome leading to life-threatening consequences. Dengue was 
previously classified into dengue fever and dengue 
haemorrhagic fever (DHF) which had four grades, with DHF III 
and IV together called as dengue shock syndrome (DSS). In 
2009, the WHO reclassified dengue due to difficulty arising in 
applying the old classification system in clinical situations and 
more reports of severe cases not fitting the criteria for DHF.  
 
The new classification emphasizes severity with patients 
being classified into 
1. dengue with or without warning signs  
2. severe dengue 
 
 
 
 
 
Specific organ impairment can also occur without shock or 
any other features of severe dengue, including hepatitis, 
encephalitis and myocarditis. Although a mild increases in 
hepatic transaminases are usually present, rarely ALT levels 
>1000 are seen with associated liver dysfunction. Dengue fever 
can also present as an acute encephalitis syndrome without other 
manifestations of the disease is increasingly seen in endemic 
areas. It is more common in children and although rarely fatal a 
handful are left with neurological sequelae. Different cardiac 
manifestations have been reported in dengue patients like acute 
myocarditis, conduction abnormalities and myocardial 
depression.These patients need to be identified early in order to 
tailor their fluid management. The clinical course consists of 
febrile, critical and recovery phases. 
  
FEBRILE PHASE 
After an usual incubation period of 5–8 days following an 
infected mosquito bite, the disease begins with a sudden onset of 
fever along with severe headache and chills, pain behind the 
eyes, particularly on eye movement, backache and pain in the 
muscles, bones and joints. These symptoms during the Spanish 
epidemic made it gain the name break bone fever. During the 
febrile period the temperature can increase high as 40°C and the 
fever may be sustained for 5–6 days and can occasionally have a 
biphasic course. Anorexia, vomiting and abdominal pain are 
also common. As the disease progresses the patient becomes 
toxic and may show marked weakness and prostration. Other 
reported symptoms include sore throat, altered taste sensation, 
constipation and depression.  
 
 
 
Several types of skin rash have been described. Initially, 
diffuse flushing, mottling or fleeting pinpoint eruptions may be  
observed on the face, neck and chest. These are transient in 
nature and occur on the 2nd day.  
A second type of skin rash is a conspicuous rash that may 
be maculopapular or scarlatiniform and appears on 
approximately the 3rd or 4th day when fever starts to subside. 
This rash starts on the chest and trunk and spreads towards the 
extremities and face and may be accompanied by itching and 
skin hyperaesthesia. Towards the end of the febrile period or 
immediately after defervescence the generalized rash fades and 
localized clusters of petechiae may appear over the dorsum of 
the feet and on the legs, hands and arms. This confluent 
petechial rash is characterized by a scattered pale round area of 
normal skin. Mild haemorrhagic complications occur during the 
febrile phase, presents as scattered petechiae on extremities, 
axillae, trunk and face. A positive tourniquet test and/or 
tendency to bruise at venepuncture sites are usually seen. 
  
Bleeding into the skin, from the nose, gums and 
gastrointestinal tract are common but haematuria is rare. The 
liver can often be enlarged, but jaundice is usually not seen 
except for liver enzyme elevation. A normal white blood count 
or leucopenia is common and neutrophils may predominate 
initially. Towards the end of the febrile phase there is a 
reduction in the number of total leucocytes and neutrophils 
shortly before or simultaneously with a relative increase in 
lymphocytes with the presence of atypical lymphocytes. The 
leucopenia usually reaches a nadir shortly before the 
temperature and platelets drop. This observation is valuable in 
marking the end of the febrile period and the beginning of the 
critical phase. Other changes include hypoproteinemia, 
hypoalbuminemia, hyponatremia and mildly elevated alanine 
aminotransferase (ALT)/aspartate aminotransferase levels 
(AST). 
CRITICAL PHASE 
It is not possible to predict who will have an uneventful 
defervescence and who will go on to develop severe dengue. 
However, using the WHO warning signs with it may be possible 
to expect complications the patients. 
 
Particular vigilance during the critical phase can help to 
identify which patients will require more intensive supportive 
therapies. The critical phase, which usually occurs at fever 
defervescence around day 5, is the period where an increase in 
the capillary permeability and plasma leakage can occur. This 
may present clinically as pleural effusion and/or ascites 
depending on the degree of plasma leakage and once the critical 
volume is lost, circulatory failure occurs. 
  The skin becomes cold and clammy and the pulse pressure 
becomes narrow (20 mmHg) with elevation of diastolic pressure 
to meet the systolic pressure. This narrowing of pulse pressure is 
the earliest marker in BP signalling impending circulatory 
failure. 
 The platelet count drops shortly before or simultaneously 
along with the haematocrit rise (20%) and both changes occur 
before the subsidence of fever and before onset of shock. 
Clotting abnormalities are usually present including 
prolongation of prothrombin and partial thromboplastin time 
and reduced fibrinogen, which has been shown to correlate to 
severity of disease but not bleeding. Without appropriate fluid 
management the patient can deteriorate into profound shock 
with an imperceptible pulse and blood pressure. Prolonged 
shock is often complicated by metabolic acidosis, multi-organ 
impairment and severe bleeding which carries a poor prognosis. 
The critical phase usually lasts for 24–48 hours, during which 
time the clinically significant plasma leakage can occur, after 
which time the recovery period begins. 
RECOVERY PHASE 
The extra vascular fluid begins to be reabsorbed over the 
next 48–72 hours. If intravenous fluids are continued into this 
period there is significant risk of fluid overload, manifesting as 
respiratory distress from pleural effusions and/or ascites. 
General symptomatic improvement is seen, with return of 
appetite, haemodynamic stability and diuresis. During this 
period, the white cell count begins to rise followed by the 
platelets, the haematocrit may drop in part due to the dilutional 
effects of the reabsorbed extravascular fluid. 
 
 
LABORATORY DIAGNOSIS: 
Diagnosis can be confirmed by serological testing and 
virus detection by molecular techniques or less frequently by 
virus isolation. No single diagnostic test performed in isolation 
is sufficiently sensitive to diagnose all the different stages of 
dengue infection. In the first 3–5 days of the infection during the 
febrile phase, RT-PCR techniques to detect DENV RNA in the 
blood are the most sensitive and specific test, however after 
defervescence, this method becomes less useful as the viraemia 
falls.  
 
Serological diagnosis by detection of anti-dengue IgM and 
IgG by enzyme-linked immunosorbent assay (ELISA) can be 
used to distinguish primary and secondary infection, but lacks 
sensitivity in the early stages of the disease. IgG serology lacks 
sensitivity in early stages of the disease and requires paired 
serum samples, it also lacks specificity due to cross reactions 
with other flaviviruses. IgM antibody capture (MAC) – ELISA 
is specific in distinguishing dengue from other flavivirus 
infections and has the advantage over the haemagglutination test 
in that a definite diagnosis can be made from an acute blood 
specimen alone, with a sensitivity of about 78%; when 
convalescent sera are tested the sensitivity is 97%. 
  IgG antibodies to dengue virus antigens increase rapidly in 
patients with secondary dengue infection. A diagnostic 
(fourfold) increase in dengue antibody by the haemagglutination 
inhibition test can be demonstrated from a paired sera obtained 
early in the febrile phase or on admission and 3–5 days later. A 
third specimen 2–3 weeks after onset is, however, required to 
confirm diagnosis of primary dengue infection. 
More recently an ELISA assay for dengue non-structural protein 
1 (NS1) detection has been developed and commercial test kits 
are now available. They are useful additions to diagnose dengue 
with excellent sensitivity and specificity in early disease, with 
limitations later on in the disease and in those with a concurrent 
humoral immune response. 
TREATMENT: 
The treatment of dengue involves various aspects of the 
disease. During early phase focus on the temperature reduction, 
during the defervesence phase focus on the optimal fluid 
management and careful watch for any bleeding signs and 
transfusion if needed. During resolution phase focussing in the 
problems with volume overload when the extravasated fluid 
reenters the blood stream. 
EARLY FEBRILE PHASE: 
Patients should be adviced to take adequate hydration and 
plenty of juice. Oral rehydration solutions may also be 
prescribed. Fever can be controlled by tepid sponging, use of 
paracetomol. The use of NSAIDS like aspirin, ibuprofen are to 
be avoided as they can irritate the gastrointestinal tract and 
aggravate vomiting and also increase the risk of gastrointestinal 
bleed. They also inhibit platelet functions which may compound 
he risks of thrombocytopenia in the defervesence phase. 
CRITICAL PHASE: 
Critical phase mainly involves the management of fluid. 
The various factors discussed above contribute to endothelial 
damage, vasodilation and increase in vascular permeability 
leading to loss of intravascular volume. During the phase it is 
essential to categorize patients to groups A-C. Group A patients 
may be advised oral fluids as much as they like with a lower 
limit of altleast 2-3L. These patients are the patients who don’t 
have any warning signs and ambulatory. 
The next group B with warning signs but stable 
haematological status are given IV maintenance fluids mostly 
ringer lactate solution at 2-3ml/Kg/hr. These patients are to 
monitored closely for any sign of deterioration to severe dengue. 
Urine output, vitals and fluid intake are to monitored every 6 
hrs. 
Group C are the patients who have severe dengue. It is 
appropriate to treat these patients in a tertiary care center with 
facilities for blood product transfusions. 
 
 
 
 
In patients presenting with shock the following algorithim is 
used. 
 
Patients at risk of major bleeding are those who have: 
–prolonged/refractory shock 
–hypotensive shock and renal or liver failure and/or severe and 
persistent metabolic acidosis; 
–given non-steroidal anti-inflammatory agents; 
–pre-existing peptic ulcer disease; 
–on anticoagulant therapy; 
–any form of trauma, including intramuscular injection. 
An useful criteria of transfusion of platelets is 
 counts less than 10,000 
 bleeding manifestation of clinical significance at any 
platelet count 
For patients with loss of blood it is better to replace with 
packed cell and clinical improvement occurs when adequate 
volume is replaced.  
Any patients with fall in hematocrit of more than 20% 
from baseline is a good candidate w requiring transfusion of 
packed cell approximately 10-20ml/Kg bodyweight. 
Preferentially fresh packed cells are to be transfused as 
stored ones have a low 2-3DPG which increases the oxygen 
affinity. Fresh packed cells have low 2-3 DPG which is optimal 
for the tissue perfusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DIFFERENTIAL DIAGNOSIS: 
 
 
 
 
 
PROTEINURIA 
        In a normal kidney, large quantities of high-molecular-
weight (HMW) proteins traverse the glomerular capillaries, 
mesangium, without entering the urine space. Capillary wall 
being charge and size selective prevents most of these protein 
from entering the tubules but for a very tiny fraction of albumin 
and other proteins. 
 
  
Proteins smaller than <20,000 Daltons can pass readily 
across the capillary wall. The concentration of such proteins in 
the plasma is very low and hence their volume in the urine 
remains very low. These low molecular weight proteins are 
reabsorbed by the proximal tubule. So, proteins likes α2-
microglobulin, apoproteins, enzymes, and other peptide 
hormones are excreted in only very small amounts in the urine. 
Most healthy persons excrete between 30 and 130 mg/day of 
protein. The upper normal limit of total protein excretion in 
urine is generally given as 150 to 200 mg/day for adults. The 
upper limit of normal albumin excretion in urine is usually 30 
mg/day. 
A very small amount of protein normally appears in the 
urine as a result of normal tubular secretion. Tamm- Horsfall 
protein is an High Molecular Weight glycoprotein which is 
formed on the epithelial surface of the thick ascending limb of 
the loop of Henle and early distal convoluted tubule. Tamm-
Horsfall protein, also known as the uromodulin, binds and 
inactivates the cytokines IL-1 and tumor necrosis factor. 
METHODS FOR MEASURING URINARY PROTEINS 
1. DIPSTICK METHOD 
This method relies on the principle that presence of protein 
in a buffer solution causes a change in the pH of the solution 
which is proportional to the concentration of  the protein. The 
dipstick contains a pH indicator dye and a buffer. The indicator 
color changes ranging from pale green to green to blue when 
stick is dipped in urine containing the proteins .The test is more 
sensitive to albumin and less sensitive to immunoglobulin light 
chains and other globulins. The test is very sensitive enough to 
detect even 20mg/dl of protein in urine. But it doesnot take into 
account the volume of urine. When urine volume is high and the 
urine is very much dilute, a relatively large amount of protein 
can even go undetected. If a total protein excretion approaching 
approximately 1 g/day may not be detected if urine output is as 
high as 10L/day as the concentration of urine protein falls below 
20mg/dl. 
 
The dipstick reports are interpreted as follows 
1. Negative <15mg % 
2. 1+   30-10mg/dl 
3. 2+   100-300mg/dl 
4.3+     300-1000mg/dl 
5. 4+     >1000 mg/dl 
 
 
 
  Extremely alkaline(pH>7) urine produces a false positive 
result. Now albumin specific dipsticks are available and these 
are very useful to detect low grade albuminuria. Some strips can 
also measure albumin: creatinine ratio. 
2. SULFOSALICYLIC ACID METHOD: 
In this commonly used method, sulfosalicylic acid is added 
to a sample of urine, and the turbidity which occurs is measured 
with help of a photometer or  nephelometer. Protein can be 
quantified through the comparison of the turbidity of the sample 
and that of a standard. This method lacks precision, and the 
variation is as high as 20%. A large number of proteins can be 
detected with this method, which includes γ-globulin light 
chains and albumin. This method is more sensitive to albumin 
than to globulins.  
Trichloroacetic acid can also be used in place of 
sulfosalicylic acid which increases the sensitivity to γ-globulin. 
False-positive reactions may also occur due to high levels of 
tolmetin sodium , tolbutamide, various antibiotics, and radio-
contrast agents.. 
3.24 HOUR URINARY PROTEIN EXCRETION: 
It gives average variation of protein excretion that occurs 
as a result of circadian rhythm and it is the most accurate 
method for monitoring proteinuria. This method detects 
albumins, globulins, and immunoglobulin light chains. This 
methods quantifies total protein rather than just albumin and 
hence his results in the detection of light chains. 
4. PROTEIN CREATININE RATIO 
The spot PCR is obtained by the ratio between urine 
protein excretion (measured by 24-Hour Protein Excretion or 
spot urine sample) and creatinine excretion, expressed as mg/mg 
or mg/mmol. Spot PCR represents a practical alternative to the 
24-hour urine collection because it is easier to obtain and is not 
influenced by variations in water intake or diuresis. And the 
same sample can also be used for investigations under 
microscope.  
A close correlation between the PCR in a random urine 
sample and the 24-hour protein excretion has been demonstrated 
in a wide range of patients, including those with different types 
of glomerulonephritis (GN) evaluated longitudinally during 
treatment. However, the results may be influenced by variations 
in creatinine excretion because it is dependent on the muscle 
mass. So in elderly and female patients, PCR values can be 
higher than the PCR in young men. The other factor to be taken 
in consideration is the timing of the sample, which can be 
influenced by the circadian fluctuation of protein excretion 
which in presence of minimal corresponding variation of 
creatinine excretion. So the best estimates are probably the ones 
obtained in the early morning.  
Some consider that a normal PCR is sufficient to rule out 
pathologic proteinuria, but that an elevated PCR should be 
confirmed and quantified with a 24-hour collection. Advantages 
of spot PCR include 
 1. Not cumbersome 
2. Not affected by diuretics or variation in water intake 
3. The sample can be used for microbial analysis 
5. SPECIFIC PROTEIN ASSAYS 
Like electrophoresis, SDS –PAGE are newer more 
sensitive and accurate methods of protein estimation. The latter 
identifies different proteins in the urine by molecular weight and 
it is also useful to find out the pattern of proteinuria. 
Immunoglobulin light chain excretion is suspected if the 
dipstick protein isnegative but 24 hour urinary protein is 
elevated. Immunofixation is used to confirm. 
Grading of Spot PCR 
Normal or mildly increased  - <150mg/g 
Moderately increased  - 150-500mg/g 
Severely increased  - >500mg/g 
 
 
 
 
 
PROTEINURIA AND DENGUE FEVER: 
The relationship between dengue and proteinuria basically 
depends on the pathogenesis underlying all the complications of 
dengue. The dengue virus after the primary period of viremia get 
into macrophages and secondary viremia then ensues. The host 
immune system then develops antibodies against the dengue 
virus. These antibodies bind with the dengue virus and form a 
complex. The viremia has a large number NS1 antigens in the 
blood circulation. This NS1 alters the glycocalyx of in the 
glomerulus and thereby reducing the negative charge. This 
reduction in negative charge alone is not enough to produce the 
proteinuria. The deposition of antigen antibody complexes in the 
endothelium causes endothelial damage which also contributes 
to the proteinuria. 
The dengue fever by various other mechanisms can also 
cause renal injury. Acute endocapillary Glomerulonephritis with 
IgG, IgM and C3 deposition presenting with hematuria, 
proteinuria and renal failure has been reported in dengue 
patients.  
Kidney involvement in dengue includes AKI, proteinuria (some-
times nephrotic), GN, and HUS. Peak proteinuria has been sug-
gested to potentially predict DHF in patients with dengue. The 
reported incidence of dengue-associated Acute Kidney Injury is 
extremely variable, from 1% to approximately 30%, but acute 
kidney injury development is a poor prognostic marker.  
Dengue-induced AKI is usually associated with  
1. shock 
2.  hemolysis,  
3.  Rhabdomyolysis 
4.  DHF grade IV and obesity in children 
5. DSS in adults 
 
 
 
 
MATERIALS AND METHODS 
 
STUDY POPULATION: 
SOURCE OF DATA: 
The study will be conducted on 100 adult dengue fever 
patients admitted in medicine wards of Government Rajaji 
Hospital & Madurai Medical College during the study period 
from march 2018 to August  2018.  
INCLUSION CRITERIA: 
• Patients admitted for fever with thrombocytopenia 
• IgM dengue ELISA positive 
• Normal serum urea/creatinine at presentation 
 EXCLUSION CRITERIA:  
• Pre existing Chronic Kidney Disease/nephrotic/nephritic 
syndrome  
• Diabetes  
• Hypertensives  
• Coronary Artery Disease 
• Female patients during menstrual cycle 
• Urinary tract infections  
 ANTICIPATED OUTCOME: 
• Urine spot protein creatinine Ratio will help in 
predicting patients at risk for progressing to severe 
dengue  
DATA COLLECTION 
Patients admitted with probable dengue will be  explained 
the purpose & procedure of study , written informed consent in 
Tamil will be obtained. The selected patients will be evaluated 
as per pro forma. Only patients with confirmed dengue by IgM 
ELISA will be included. 
Daily morning first void clean catch mid stream urine will 
be collected and sent for analysis. Daily morning complete 
blood counts are also collected.  
 
LABORATORY INVESTIGATIONS 
1. Complete blood count 
2. Blood sugar 
3. Serum urea 
4. Serum creatinine  
5. Daily morning first void mid stream urine spot protein 
creatinine Ratio 
6. IgM ELISA for dengue 
7. Ultra sonogram of abdomen 
DESIGN OF STUDY: 
Prospective study. 
PERIOD OF STUDY: 
6 MONTHS (MARCH 2018 to AUGUST 2018) 
COLLABORATING DEPARTMENTS: 
DEPARTMENT OF GENERAL MEDICINE 
DEPARTMENT OF BIOCHEMISTRY 
DEPARTMENT OF RADIOLOGY 
 
 
ETHICAL CLEARANCE: OBTAINED 
CONSENT: Individual written and informed consent 
CONFLICT OF INTEREST: Nil 
FINANCIAL SUPPORT: Self 
 
DATA ANALYSIS: 
Data entry was done in excel spread sheets and 
statistical analysis was done using sigmastat software. Chi 
square test was used in the analysis for p value between spot 
PCR and occurrence of DHF/DSS. The analysis of data was 
carried out by entering the coded information and generating 
tables. The data will be presented using descriptive statistics 
in form of tables and graphs. Results are expressed as 
proportions with 95% confidence interval. Univariate 
analysis was carried out using non –parametric Mann 
Whitney Test to compare the various parameters between 
two groups. 
 
PROFORMA 
 
Name: 
Age / Sex:    Residence: Rural / Urban   
Occupation: 
Total duration of illness : 
Presenting complaints: 
Past History: 
H/o DM, HT, CKD, CVD, CAD, Thyroid disorders, 
Alcohol intake 
Menstrual history:                         
Clinical Examination: 
General Examination: 
Consciousness,  
Pallor,  
Cyanosis      
Jaundice,  
Clubbing,  
Lymphadenopathy,  
Pedal oedema 
Vitals: 
PR 
BP 
RR 
SpO2 
 
Anthropometric measures: 
Height (cm):       Weight (kg):                   BMI: 
Systemic examination: 
CVS: 
 
RS: 
 
ABDOMEN: 
 
 
CNS: 
 
 
*Day 0 is taken as the day of defervescence 
 
 
 Day -1 Day 0* Day 1 Day 2 Day 3 Day 4 
Spot PCR       
Platelet 
count 
      
Warning 
signs 
      
Required 
transfusion 
      
hypotension       
RESULTS AND INTERPRETATION 
 
Table 1: Age distribution among study population 
Age in years No. of cases 
<20 10 
20-40 51 
>40 39 
Total 100 
 
 
Of the total 100 patients, those of age less than 20 constituted were 10, 
between 20-40 yrs were 51 nad more than 40 were 39. 
 
 Table 2: Sex distribution among study population 
Sex No. of cases 
Male 60 
Female 40 
Total 100 
 
 
 
 
 
 
Among the subjects the total number of men were more accounting 60 
and female were 40. 
Table 3: Distribution of urine Spot PCR among study 
population 
 
SPOT PCR No. of cases 
< 560 mg/g 76 
> 560 mg/g 24 
Total 100 
 
 
 
 
Among the total 100 patients 24 had urine Spot PCR more than 560 mg/g 
and 76 had urine spot PCR less 560 mg/g. 
 Table 4: Age wise distribution among DHF patients 
 
 
 
 
 
 
 
 
 
 
Among the < 20 yrs age group there was 40 % incidence of DHF, among 
the 20-40 yrs group incidence was 13% and among the >40yrs group it 
was 20.5%. 
 
Age vs DHF 
transfusion(DHF) 
Yes No 
<20 (10) 4 6 
20-40 (51) 7 44 
>40 (39) 8 31 
Total 19 81 
Table 5:Age wise distribution among DSS patients 
 
Age vs DSS 
DSS 
Yes No 
<20 (10) 5 5 
20-40 (51) 6 45 
>40 (39) 10 29 
Total 21 79 
 
 
 
 
On seeing the age related incidence of DSS in <20yrs age group it was 
50%,in 20-40yrs age group 11.7% and among the >40 yrs group it was 
25.6%. 
Table 6: Sex distribution among DHF patients 
 
Sex vs DHF 
transfusion(DHF) 
Yes No 
Male (60) 10 50 
Female (40) 9 31 
Total 19 81 
 
 
 
In the sex related distrubtion DHF occurred in 10 men and 19 women. 
The incidence was 16.6% among men and 21.9% among women. 
 Table 7:Sex distribution among DSS patients 
 
Sex vs DSS 
DSS 
Yes No 
Male (60) 12 48 
Female (40) 9 31 
Total 21 79 
 
 
  
Of the total 21 patients with DSS 12 were male and 9 were female. 
Table 8: Patients with proteinuria >560 mg/g with 
DHF 
DHF in patients with proteinuria >560 mg/g 
YES 15 
NO 9 
TOTAL 24 
 
 
 
Among the 24 patients with proteinuria more than 560 mg/g 15 went for 
DHF and 8 did not have DHF. 
Table 9: Platelet count in patients with proteinuria < 
560mg/g 
platelet count in proteinuria <560mg/g 
  
  
Platelet count Mean S.D 
day -1 93000 22811.693 
0 72605 20823.115 
1 61118 25111.998 
day 2 80934.2 39809.324 
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 Table 10: Platelet count in patients with proteinuria 
>560mg/g 
 
   proteinuria vs platelet 
count     
proteinuria vs < 560 Mean S.D 
P -1 93000 22811.693 
0 72605 20823.115 
1 61118 25111.998 
P 2 80934.2 39809.324 
Table 11:DSS in patients with proteinuria >560mg/g 
 
 
 
 
 
 
Among the 24 patients with proteinuria more than 560 mg/g 13 patients 
went for DSS. 
 
DSS vs in patients with > 560mg/g 
proteinuria 
YES 13 
NO 11 
TOTAL 24 
Significance of Proteinuria Vs DHF/DSS 
Proteinuria DHF / DSS NO DHF / DSS 
> 560 mg/g (24) 21 3 
< 560 mg/g  (76) 8 68 
p value <0.001 Significant 
 
In patients with proteinuria > 560 mg/g  21 patients went 
for DHF/DSS and only three had no progression. Among those 
with proteinuria less than 560 mg/g only 8 went for DHF/DSS 
of the total 76. The p value is significant with a confidence 
interval of 95%. 
 
 
  
DISCUSSION 
 
In our study the incidence of dengue hemorrhage fever 
was 19 % and dengue shock syndrome was 21%. The proteiuria 
above 560 mg/g occurred in 24 patients among which 87% went 
for a either dengue hemorrhagic fever or dengue shock 
syndrome.10 patients had manifestations of both dengue shock 
syndrome and dengue hemrhagic fever. Urine spot PCR was 
used a measure for proteinuria because commercial kit for 
albuminuria did not measure other proteins and quatification 
with 24 hr urine protein would be cumbersome 
The use of urine spot PCR above 560 mg/g had a very 
significant correlation with development of DHF/DSS. It had a 
specificity of about 95 %. And a sensitivity of 72.4%.  The test 
also had a positive predictive value of 87.5 %  and a negative 
predictive value of 89.4%. 
In a study by vasanwala et al in 2014 which used a cut off  
value of 29mg/mmol of Spot PCR, it had a sensitivity of 76% 
and specificity of 77%. When it was combined with platelet 
value and age adjustment the sensitivity rose to 90% and 
specificity to 80%. The higher Spot PCR cut off used in our 
study could explain for the higher specificity and lower 
sensitivity seen in our study. 
Like in their study the nadir of the platelet values occurred 
within 2 days around of defervesence. The peak value in the 
study by vasanwala et al occurred around day of defervesence. 
So this study was done using the Spot PCR on day of 
defervesence. 
Another study by Andries et al. in Cambodia found that 
urine diptick test was not efficient to triage the dengue patients. 
Our study concurs with the study in that the urine proteinuria 
was higher in patients with DHF and DSS. The andries et al 
study was done in children. The study also went ahead with 
urine protein electrophoresis and “Patterns compatible with a 
tubular proteinuria, a selective glomerular proteinuria and a 
nonselective glomerular proteinuria, were observed in 51.9%, 
22.2% and 14.8% of the samples tested by UPEP, respectively.” 
SUMMARY 
 
 Of the total 100 patients, those of age less than 20 
constituted were 10, between 20-40 yrs were 51 and more 
than 40 were 39. 
 Among the subjects the total number of men were more 
accounting 60 and female were 40. 
 Among the total 100 patients 24 had urine Spot PCR more 
than 560 mg/g and 76 had urine spot PCR less 560 mg/g. 
 Among the < 20 yrs age group there was 40 % incidence 
of DHF, among the 20-40 yrs group incidence was 13% 
and among the >40yrs group it was 20.5%. 
 On seeing the age related incidence of DSS in <20yrs age 
group it was 50%,in 20-40yrs age group 11.7% and among 
the >40 yrs group it was 25.6%. 
 In the sex related distribution DHF occurred in 10 men and 
19 women. The incidence was 16.6% among men and 
21.9% among women. 
 Among the 24 patients with proteinuria more than 560 
mg/g  15 went for DHF and 8 did not have DHF 
 Among the 24 patients with proteinuria more than 560 
mg/g 13 patients went for DSS. 
 In patients with proteinuria > 560 mg/g 21 patients went 
for DHF/DSS and only three had no progression. Among 
those with proteinuria less than 560 mg/g only 8 went for 
DHF/DSS of the total 76. 
 In our study urine spot PCR >560 mg/g had a specificity of 
about 95 %. And a sensitivity of 72.4%.  The test also had 
a positive predictive value of 87.5 % and a negative 
predictive value of 89.4%. 
 
 
 
LIMITATIONS 
 
 The nature of proteinuria was not segregated by 
electrophoresis 
 Children in were not included in the study 
 Being a tertiary hospital most patients were referred from 
primary center this may have caused the skew in incidence 
of the complications 
 Renal biopsy was not done to document the 
glomerulonephritis as it was usually self limiting.  
 
 
 
CONCLUSION 
 
There is a need to risk stratify patients with dengue fever, 
Particularly during the periods of epidemics. The fall in platelet 
count can predict only to some extent the occurrence of DHF. 
Urine proteinuria can be used as an additional factor to predict 
the risk of both DHF and DSS. The peak of urine proteinuria 
occurs around the day of defervesence. Therefore urine spot 
PCR can be used as a specific marker for prediction of dengue 
hemorrhagic fever and Dengue shock syndrome. So patients 
with higher spot PCR need to shifted to facility with more 
intensive monitoring than others. The use of urine spot PCR is 
not recommened as the sensivity of the test based on our study 
results were low. The test also has a high positive predictive 
value and also a high predictive value. The dengue algorithm 
using various clinical biochemical parameters may also be used 
for predicting the complications. 
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இ ்தஆராய்சச்ியின்விவரங்களும்அதன்த ாக்கங்களும்
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 ான்என்னுகடயசுய ிகனவுடன்மே்றும்முழுசுத ்திரத்
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MASTER CHART 
 
S.N
o. 
AG
E 
SEX  
SPOT 
PCR 
-1 0 1 2 transfusion(D
HF) 
DSS 
1 17 female 1250 65000 21000 8000 34000 yes no 
2 18 female 103 47000 43000 58000 86000 no no 
3 45 female 2161 24000 21000 15000 11000 no yes 
4 43 female 350 63000 24000 13000 17000 no no 
5 19 female 1091 62000 47000 21000 19000 no yes 
6 20 female 444 48000 24000 21000 23000 no no 
7 21 female 667 48000 40000 26000 45000 no no 
8 18 female 656 58000 39000 15000 9000 yes yes 
9 30 female 643 24000 14000 9000 21000 yes no 
10 19 male 968 56000 20000 11000 19000 yes yes 
11 25 male 1470 78000 39000 21000 19000 yes  no 
12 46 male 1435 64000 22000 6000 1000 yes  yes 
13 47 male 1144 85000 65000 45000 44000 yes no 
14 18 male 960 96000 92000 95000 11100
0 
no yes 
15 24 male 1605 35000 21000 11000 27000 no no 
16 52 male 1308 66000 35000 21000 41000 yes yes 
17 32 male 1647 113000 56000 19000 26000 yes no 
18 29 male 1501 78000 32000 11000 6000 no yes 
19 52 male 1350 92000 40000 9000 16000 no no 
20 33 male 829 69000 30000 6000 13000 no  yes 
21 50 male 1659 91000 63000 23000 9000 yes no 
22 55 male 1337 96000 52000 10000 15000 yes yes 
23 26 male 1792 58000 32000 11000 6000 yes yes 
24 47 male 1567 86000 56000 22000 19000 no  yes 
25 34 female 922 63000 54000 25000 9000 yes no 
26 29 female 1260 77000 36000 5000 9000 yes no 
27 52 female 1742 65000 26000 15000 8000 yes  yes 
28 54 female 256 70000 56000 30000 48000 no no 
29 26 female 192 105000 90000 88000 11200
0 
no no 
30 35 female 229 62000 50000 36000 60000 no no 
31 20 female 462 62000 36000 21000 43000 no no 
32 36 female 197 78000 70000 98000 15200
0 
no no 
33 52 female 378 125000 90000 14000
0 
21000
0 
no no 
34 48 female 234 63000 51000 78000 13000
0 
no no 
35 47 female 460 61000 42000 25000 39000 no no 
36 34 female 377 130000 96000 82000 98000 no no 
37 28 female 378 98000 89000 72000 83000 no no 
38 50 female 367 68000 37000 22000 56000 no no 
39 43 female 467 76000 70000 52000 58000 no no 
40 39 female 396 64000 58000 54000 69000 no no 
41 44 female 130 94000 85000 80000 12000
0 
no no 
42 27 female 235 70000 52000 35000 68000 no no 
43 27 male 445 71000 60000 62000 88000 no no 
44 25 male 389 92000 90000 96000 15200
0 
no no 
45 40 male 318 77000 86000 94000 14800
0 
no no 
46 25 male 211 109000 87000 46000 98000 no no 
47 55 male 518 76000 32000 16000 24000 no yes 
48 35 male 257 62000 58000 49000 55000 no no 
49 38 male 416 114000 92000 90000 14000
0 
no no 
50 55 male 481 130000 110000 88000 96000 no no 
51 22 male 332 122000 95000 60000 88000 no no 
52 46 male 340 65000 53000 31000 45000 no yes 
53 21 male 123 88000 74000 62000 98000 no no 
54 19 male 322 75000 52000 60000 92000 no no 
55 51 male 394 90000 78000 70000 86000 no no 
56 51 male 204 124000 95000 84000 11000
0 
no no 
57 22 male 381 77000 54000 80000 13000
0 
no no 
58 34 male 300 100000 85000 98000 13000
0 
no no 
59 43 male 385 118000 99000 80000 94000 no no 
60 46 male 310 71000 68000 78000 95000 no no 
61 38 male 460 130000 99000 65000 80000 no no 
62 23 male 415 97000 82000 65000 70000 no no 
63 22 male 508 105000 80000 56000 62000 no no 
64 54 male 492 109000 98000 82000 86000 no no 
65 35 male 311 121000 94000 92000 13300
0 
no no 
66 22 male 246 102000 78000 82000 91000 no no 
67 54 male 348 130000 94000 82000 98000 no no 
68 52 male 187 108000 93000 70000 81000 no no 
69 23 male 166 77000 54000 36000 40000 no no 
70 32 male 118 74000 62000 54000 68000 no no 
71 39 male 425 95000 90000 71000 12000
0 
no no 
72 47 male 152 112000 82000 86000 94000 no no 
73 48 male 130 94000 72000 63000 85000 no no 
74 30 male 372 102000 85000 61000 75000 no no 
75 52 male 150 94000 82000 56000 72000 no no 
76 28 male 541 118000 89000 71000 82000 no no 
77 33 male 366 99000 75000 32000 45000 no no 
78 20 male 211 94000 82000 45000 54000 no no 
79 17 male 281 77000 54000 25000 13000 yes no 
80 19 male 493 101000 79000 45000 30000 no yes 
81 43 male 186 114000 85000 45000 62000 no no 
82 28 male 202 76000 89000 96000 16500
0 
no no 
83 42 male 451 86000 72000 61000 78000 no no 
84 16 male 321 122000 94000 64000 82000 no no 
85 21 female 421 85000 50000 22000 16000 no yes 
86 40 female 166 118000 97000 90000 13000
0 
no no 
87 31 female 518 103000 60000 51000 31000 no yes 
88 52 female 541 62000 54000 31000 12000 yes yes 
89 41 male 211 87000 61000 46000 51000 no no 
90 35 female 508 64000 32000 24000 5000 yes yes 
91 30 female 143 114000 87000 54000 68000 no no 
92 26 female 276 101000 89000 63000 87000 no no 
93 27 female 423 130000 110000 85000 99000 no no 
94 46 female 531 89000 71000 95000 13100
0 
no no 
95 28 female 140 118000 65000 72000 89000 no no 
96 50 female 319 126000 75000 52000 84000 no no 
97 29 female 124 115000 99000 81000 94000 no no 
98 45 male 105 116000 65000 55000 75000 no no 
99 46 male 98 96000 54000 39000 60000 no  no 
100 52 female 541 62000 54000 31000 12000 yes yes 
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